o. acikgoz Et Al. , "The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients," ACTA ONCOLOGICA TURCICA , vol.56, no.2, pp.153-160, 2023
acikgoz, o. Et Al. 2023. The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients. ACTA ONCOLOGICA TURCICA , vol.56, no.2 , 153-160.
acikgoz, o., Göktaş Aydın, S., Bilici, A., Kutlu, Y., Muglu, H., Karcı, E., ... J.(2023). The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients. ACTA ONCOLOGICA TURCICA , vol.56, no.2, 153-160.
acikgoz, Özgür Et Al. "The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients," ACTA ONCOLOGICA TURCICA , vol.56, no.2, 153-160, 2023
acikgoz, Özgür Et Al. "The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients." ACTA ONCOLOGICA TURCICA , vol.56, no.2, pp.153-160, 2023
acikgoz, o. Et Al. (2023) . "The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients." ACTA ONCOLOGICA TURCICA , vol.56, no.2, pp.153-160.
@article{article, author={Özgür AÇIKGÖZ Et Al. }, title={The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients}, journal={ACTA ONCOLOGICA TURCICA}, year=2023, pages={153-160} }